SMC negative on Celgene's Imnovid for MM but approves Genzyme's Lemtrada for MS

The Scottish Medicines Consortium has issued guidance not to recommend US biotech company Celgene’s (Nasdaq: CELG) drug Imnovid (pomalidomide) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, while it has approved a multiple sclerosis treatment developed by Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN).

Block to Celgene’s Imnovid in Scotland

The SMC said that Celgene did not present a sufficiently robust economic analysis and that its justification of the treatment’s cost in relation to its benefits was insufficient to gain its acceptance.